Illumina adds Eli Lilly's Dr. Skovronsky to board to boost genomics innovation

Illumina appointed Dr. Daniel M. Skovronsky, Chief Scientific and Product Officer at Eli Lilly, to its Board of Directors. His expertise in drug discovery and clinical development aligns with Illumina's focus on genomics and multiomics innovation. This move aims to strengthen Illumina's leadership in precision medicine and genomic technologies. Dr. Skovronsky's background includes leading Lilly's global R&D and founding a biotech company, adding valuable scientific and strategic insight to Illumina's board.